FDA Expects Closing Gap On NDI Notifications To Open Window Wider On Supplements Sold In US
Executive Summary
FDA regulatory framework for VMS product manufacturing and marketing provides little pre-market transparency into what’s available in US, but it’s clear from post-market monitoring by the Office of Dietary Supplement Programs that compliance with the NDI notification requirement is lax.
You may also be interested in...
US FDA Plans To Publish NDI Notifications Revised Draft Guidance In Sections
FDA includes explanation of plans for revising latest draft guidance, made available in 2016, based on stakeholders’ responses with its annual estimate of supplement industry’s burden for NDIN compliance.
Dietary Ingredient Studies For Health Benefits Could Be Fenced In By US FDA IND Proposal
Proposed rule introduces two exemptions agency would allow from needing IND clearance for clinical investigations to evaluate food, supplements or cosmetics. Both begin with basic requirement of trial not intended to support drug development plan or labeling change that would make a food, dietary ingredient or cosmetic an unlawfully marketed drug.
US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond
More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.